글리메피리드
Glimepiride
1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea
다른 이름: Amarel · Amarylle · Euglim · Glimepil · Solosa · Roname · HOE-490
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Treatment of NIDDM | 2 mg (total dose) per cat | PO | once daily | — | 🌎 NA |
| Treatment of NIDDM | 1-2 mg (total dose per cat) | PO | once daily | — | 🌎 NA |
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
경구용, 1일 1회 투여하는 항고혈당제입니다. 고양이의 인슐린 비의존성 당뇨병(NIDDM) 보조 치료에 유용할 수 있습니다. 고양이에서의 사용 경험은 매우 제한적입니다.
작용 기전
Glimepiride is a medium- to long-acting secretagogue sulfonylurea.
Primary Mechanism:
- Binds to the SUR1 receptor on the membrane of functioning pancreatic beta cells.
- Closes ATP-sensitive potassium (K+) channels → cell depolarization.
- Opens voltage-gated calcium (Ca2+) channels → calcium influx.
- Triggers the exocytosis and release of insulin granules into the bloodstream.
Secondary Mechanism:
- With continued use, it may also increase peripheral tissue sensitivity to insulin, reducing insulin resistance.
안전성·주의사항
금기사항
- Hypersensitivity to glimepiride or other sulfonylureas
- Diabetic ketoacidosis (DKA)
부작용
- Hypoglycemia
- Dizziness
- Asthenia
- Liver function impairment (rare)
- Allergic respiratory reactions (rare)
- Dermatologic reactions (rare)
- Hematologic reactions (rare)
주의
Warning: Do not confuse glimepiride with other sulfonylureas such as glipizide or glyburide.
- Pregnancy: FDA Category C. Animal studies show intrauterine deaths secondary to maternal hypoglycemia. Avoid use during pregnancy.
- Nursing: Excreted in maternal milk; manufacturer recommends discontinuing in nursing mothers.
- Hepatic/Renal Impairment: Use with caution as metabolism and excretion may be delayed, increasing the risk of hypoglycemia.
약물 상호작용
May increase plasma levels of glimepiride
May potentiate hypoglycemic effect
May displace glimepiride from plasma proteins
May reduce efficacy
May reduce hypoglycemic efficacy
May reduce hypoglycemic efficacy
May reduce hypoglycemic efficacy
May reduce hypoglycemic efficacy
May reduce hypoglycemic efficacy
May displace glimepiride from plasma proteins
May reduce hypoglycemic efficacy
May displace glimepiride from plasma proteins
모니터링
- Fasting blood glucose
- Appetite and attitude
- Body condition
- PU/PD resolution
- Serum fructosamine
- Glycosylated hemoglobin levels
- Signs of hypoglycemia
약동학
흡수
In humans, completely absorbed from the GI tract. Peak levels occur in 2-3 hours; food delays the peak somewhat and lowers AUC by about 9%.
분포
Volume of distribution is 0.11 L/kg; the drug is greater than 99% bound to plasma proteins (in humans).
대사
Hepatically metabolized to at least two major metabolites. One of these, M1, has activity at about 1/3 that of the parent compound.
배설
Clearance is 48 mL/min. Approximately 60% of the drug (as metabolites) is excreted into the urine and the remainder in the feces. Has a 24-hour duration of activity in humans.
과다투여
Overdoses can lead to hypoglycemia, ranging from mild to severe and life-threatening.
Treatment:
- Immediate glucose administration (oral if conscious, IV dextrose if severe/unconscious).
- Intensive monitoring is critical.
- Due to the drug's long duration of activity, patients may require continuous glucose support (e.g., IV dextrose CRI) for at least 48 hours post-ingestion, even after apparent clinical recovery.
제품
제형
- Oral Tablets
인용의약품
- Glimepiride Oral Tablets: 1 mg, 2 mg, & 4 mg; Amaryl, generic; (Rx)
규제 현황
규제 데이터 없음: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Glimepiride tablets should be stored between 15-30°C (59-86°F) in well-closed containers.
보호자 정보
이 약물을 고양이에게 사용하는 것은 '시험적' 성격이 있음을 이해해야 하며, 부작용(저혈당으로 인한 무기력, 떨림, 발작 등)이 발생하면 즉시 수의사에게 알려야 합니다.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.